In 2016 Kevin Widmer graduated as a pharmacist at the Department of Pharmaceutical Science of the University of Basel, and gained his federal diploma in the same year.
He conducted his master thesis at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego in 2015. Under the supervision of Prof. Ruben Abagyan, and with support from Prof. Beat Ernst of the University of Basel, he employed a computational research approach to analyze and characterize different cysteine peptidases from parasitic organisms.
Kevin Widmer joined the Molecular Pharmacy group of Prof. Daniel Ricklin in April 2017. He is currently working on the analysis of microbial immune evasion proteins and components of the complement system, with the aim to find new inhibitors for the therapeutic attenuation of complement initiation pathways.